DK2603206T3 - Farmaceutiske sammensætninger af metabotrofisk glutamat 5 receptor (mglu5)-antagonister - Google Patents

Farmaceutiske sammensætninger af metabotrofisk glutamat 5 receptor (mglu5)-antagonister

Info

Publication number
DK2603206T3
DK2603206T3 DK11746215.0T DK11746215T DK2603206T3 DK 2603206 T3 DK2603206 T3 DK 2603206T3 DK 11746215 T DK11746215 T DK 11746215T DK 2603206 T3 DK2603206 T3 DK 2603206T3
Authority
DK
Denmark
Prior art keywords
mglu5
antagonists
receptor
pharmaceutical compositions
metabotrophic glutamate
Prior art date
Application number
DK11746215.0T
Other languages
Danish (da)
English (en)
Inventor
Ashish Chatterji
Jingjun Huang
Stephanie Koennings
Kai Lindenstruth
Harpreet K Sandhu
Navnit Hargovindas Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK2603206T3 publication Critical patent/DK2603206T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK11746215.0T 2010-08-11 2011-08-08 Farmaceutiske sammensætninger af metabotrofisk glutamat 5 receptor (mglu5)-antagonister DK2603206T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37269310P 2010-08-11 2010-08-11
PCT/EP2011/063602 WO2012019989A2 (en) 2010-08-11 2011-08-08 Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists

Publications (1)

Publication Number Publication Date
DK2603206T3 true DK2603206T3 (da) 2017-01-02

Family

ID=44509316

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11746215.0T DK2603206T3 (da) 2010-08-11 2011-08-08 Farmaceutiske sammensætninger af metabotrofisk glutamat 5 receptor (mglu5)-antagonister

Country Status (24)

Country Link
US (5) US20120039999A1 (hu)
EP (2) EP2808022A1 (hu)
JP (2) JP2013533299A (hu)
KR (2) KR101800518B1 (hu)
CN (2) CN105012301B (hu)
AR (1) AR082602A1 (hu)
AU (1) AU2011288555B2 (hu)
BR (1) BR112013003158B1 (hu)
CA (1) CA2804749C (hu)
DK (1) DK2603206T3 (hu)
ES (1) ES2608727T3 (hu)
HK (1) HK1181653A1 (hu)
HU (1) HUE031220T2 (hu)
IL (1) IL224032B (hu)
MX (1) MX338634B (hu)
MY (1) MY164306A (hu)
NZ (1) NZ605424A (hu)
PL (1) PL2603206T3 (hu)
RU (1) RU2602955C2 (hu)
SG (1) SG187550A1 (hu)
SI (1) SI2603206T1 (hu)
TW (1) TW201211024A (hu)
WO (1) WO2012019989A2 (hu)
ZA (1) ZA201300500B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014199316A1 (en) * 2013-06-12 2014-12-18 Novartis Ag Modified release formulation
JO3543B1 (ar) * 2015-09-28 2020-07-05 Applied Pharma Res تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم
US10898444B2 (en) 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
JP2020529975A (ja) 2017-07-31 2020-10-15 ノバルティス アーゲー コカイン使用の低減又はコカイン使用再燃の予防におけるマボグルラントの使用
AU2021285273A1 (en) 2020-06-05 2023-01-19 Noema Pharma Ag Methods of treatment of tuberous sclerosis complex

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
ZA881301B (en) * 1987-02-27 1989-10-25 Lilly Co Eli Sustained release matrix formulations
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
FR2677886B1 (fr) 1991-06-18 1995-03-31 Adir Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale.
US5656291A (en) 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
CN1094948A (zh) * 1993-05-13 1994-11-16 格拉克索加拿大有限公司 控制释放装置
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
CA2383220C (en) * 1999-09-02 2009-11-03 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
AU2001246861A1 (en) * 2000-04-10 2001-10-23 Sumitomo Pharmaceuticals Co. Ltd. Sustained release preparations
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
BRPI0511678A (pt) 2004-06-01 2008-01-08 Hoffmann La Roche piridin-4-il-etinil-imidazóis e pirazóis como antagonistas de receptor de mglu5
EP1756086B1 (en) * 2004-06-01 2008-06-04 F.Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
EP1681056A1 (en) * 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
ES2577391T3 (es) * 2006-12-21 2016-07-14 F. Hoffmann-La Roche Ag Polimorfos de un antagonista del receptor mglur5
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists

Also Published As

Publication number Publication date
KR20130028991A (ko) 2013-03-20
EP2603206A2 (en) 2013-06-19
BR112013003158B1 (pt) 2021-07-06
SI2603206T1 (sl) 2017-01-31
KR20150034254A (ko) 2015-04-02
JP2013533299A (ja) 2013-08-22
US20190216789A1 (en) 2019-07-18
CN103068374B (zh) 2015-08-26
AU2011288555A1 (en) 2013-01-24
US20220241260A9 (en) 2022-08-04
TW201211024A (en) 2012-03-16
AR082602A1 (es) 2012-12-19
BR112013003158A2 (pt) 2016-06-28
CN103068374A (zh) 2013-04-24
HUE031220T2 (hu) 2017-07-28
US20120039999A1 (en) 2012-02-16
NZ605424A (en) 2015-01-30
MX2013000860A (es) 2013-02-27
US20170202819A1 (en) 2017-07-20
ES2608727T3 (es) 2017-04-12
MX338634B (es) 2016-04-26
MY164306A (en) 2017-12-15
CA2804749A1 (en) 2012-02-16
PL2603206T3 (pl) 2017-10-31
US20210052567A1 (en) 2021-02-25
JP6113203B2 (ja) 2017-04-12
EP2603206B1 (en) 2016-11-02
IL224032B (en) 2018-03-29
WO2012019989A3 (en) 2012-08-02
RU2602955C2 (ru) 2016-11-20
US20150140087A1 (en) 2015-05-21
SG187550A1 (en) 2013-03-28
HK1181653A1 (en) 2013-11-15
WO2012019989A2 (en) 2012-02-16
JP2015107986A (ja) 2015-06-11
CN105012301A (zh) 2015-11-04
CN105012301B (zh) 2018-09-11
CA2804749C (en) 2018-05-22
KR101800518B1 (ko) 2017-11-22
ZA201300500B (en) 2013-09-25
AU2011288555B2 (en) 2016-02-18
RU2013108057A (ru) 2014-09-20
EP2808022A1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
CY2023022I1 (el) Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης
DK3156056T3 (da) Farmaceutiske sammensætninger der består af sorbitanestere
SMT201600350B (it) Composizioni farmaceutiche
BR112012003263A2 (pt) formulações intravenosas de antagonistas de neuroquinina-1
DK3170501T3 (da) Antagonister af cb1-receptor
DK3284467T3 (da) Nikotinholdige farmaceutiske sammensætninger
DK2872491T3 (da) Inhibitorer af fibroblastvækstfaktorreceptoren
BR112013009636A2 (pt) terapias à base de ligante de receptor quimiossensorial
DK2129654T3 (da) Antagonister af glucagonreceptoren
DK3192500T3 (da) Sammensætninger til kontinuerlig indgivelse af dopa-decarboxylasehæmmere
DK2817000T3 (da) Orale farmaceutiske sammensætninger af dabigatranetexilat
DK2498756T4 (da) Tabletformuleringer af neratinibmaleat
BR112014003052A2 (pt) composições farmacêuticas
DK3721904T3 (da) Formuleringer af t1h-antistof
DK2528602T4 (da) Formuleringer af bendamustin
BR112013009635A2 (pt) terapias à base de ligante de receptor quimiossensorial
SMT201600078B (it) Antagonista del recettore per cgrp
CO6930367A2 (es) Composiciones farmaceúticas
DK2408446T3 (da) Anvendelse af farmaceutiske sammensætninger, der indeholder mesembrenon
DK3106150T3 (da) Forbedrede farmaceutiske sammensætninger af pimobendan
HK1181654A1 (zh) 代謝型谷氨酸受體 拮抗劑的藥物組合物
SMT201500296B (it) Antagonisti del recettore trpm8
DK2800572T3 (da) Sammensætning af ellagitannin-rige ekstrakter
DK2606042T3 (da) Disubstituerede tetrahydrofuranyl-forbindelser som antagonister af bradykinin-b1-receptor
DK2603509T3 (da) KRYSTALLINSK FORM AF PYRIMIDIO [6,1- a] ISOQUINOLIN-4-ON-FORBINDELSE